B 细胞相关表面分子 CD40 的简史。
A Short History of the B-Cell-Associated Surface Molecule CD40.
机构信息
Department of Immunology, University of Washington , Seattle, WA , USA.
出版信息
Front Immunol. 2014 Sep 29;5:472. doi: 10.3389/fimmu.2014.00472. eCollection 2014.
Abstract
This perspective traces developments using monoclonal antibody technology that led to the discovery of CD40, a receptor that on B cells mediates "T cell help" and on dendritic cells helps to program CD8 T cell responses. I discuss some things that we got right during the path of discovery and some things we missed. Immunotherapies that block or stimulate the CD40 pathway hold great promise for treatment of autoimmune diseases and cancers.
摘要
这篇观点文章追溯了单克隆抗体技术的发展历程，该技术导致了 CD40 的发现，CD40 是一种受体，在 B 细胞上介导“T 细胞辅助”，在树突状细胞上有助于编程 CD8 T 细胞反应。我讨论了在发现过程中我们做对的一些事情和错过的一些事情。阻断或刺激 CD40 途径的免疫疗法为治疗自身免疫性疾病和癌症带来了巨大的希望。
相似文献
1
A Short History of the B-Cell-Associated Surface Molecule CD40.B 细胞相关表面分子 CD40 的简史。
Front Immunol. 2014 Sep 29;5:472. doi: 10.3389/fimmu.2014.00472. eCollection 2014.
2
Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8(+) and CD4(+) T Cells.CD40 和树突状细胞表面凝集素对外源抗原呈递给 CD8(+)和 CD4(+)T 细胞的功能特化作用。
EBioMedicine. 2016 Jan 28;5:46-58. doi: 10.1016/j.ebiom.2016.01.029. eCollection 2016 Mar.
3
Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.激动型CD40抗体CP-870,893对人B细胞的激活作用以及同时进行Toll样受体9刺激后的增强作用。
J Transl Med. 2009 Nov 11;7:93. doi: 10.1186/1479-5876-7-93.
4
Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment.舒尼替尼通过减少髓源性抑制细胞（MDSCs）并协同改善内皮细胞活化和T细胞募集，增强了激动性CD40抗体的抗肿瘤反应。
Oncotarget. 2016 Jul 1;7(31):50277-50289. doi: 10.18632/oncotarget.10364.
5
Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.在恒河猴中，将HIV-1包膜糖蛋白gp140靶向CD40与靶向凝集素样氧化低密度脂蛋白受体1（LOX-1）相比，并结合具有复制能力的NYVAC-KC，在诱导Env特异性抗体和T细胞反应方面的优势。
J Virol. 2017 Apr 13;91(9). doi: 10.1128/JVI.01596-16. Print 2017 May 1.
6
Anti-CD40-induced inflammatory E-cadherin+ dendritic cells enhance T cell responses and antitumour immunity in murine Lewis lung carcinoma.抗CD40诱导的炎性E-钙黏蛋白阳性树突状细胞增强小鼠Lewis肺癌中的T细胞反应和抗肿瘤免疫。
J Exp Clin Cancer Res. 2015 Feb 5;34(1):11. doi: 10.1186/s13046-015-0126-9.
7
CD40-CD40 ligand interaction between dendritic cells and CD8+ T cells is needed to stimulate maximal T cell responses in the absence of CD4+ T cell help.在缺乏CD4 + T细胞辅助的情况下，树突状细胞与CD8 + T细胞之间的CD40 - CD40配体相互作用是刺激最大T细胞反应所必需的。
J Immunol. 2007 Mar 1;178(5):2844-52. doi: 10.4049/jimmunol.178.5.2844.
8
Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.表达CD40配体的非复制型重组痘苗病毒可增强抗原呈递细胞刺激特异性CD4⁺和CD8⁺T细胞反应的能力。
Hum Gene Ther. 2005 Mar;16(3):348-60. doi: 10.1089/hum.2005.16.348.
9
CD40 cross-linking inhibits specific antibody production by human B cells.CD40交联可抑制人B细胞产生特异性抗体。
Int Immunol. 1995 Nov;7(11):1809-15. doi: 10.1093/intimm/7.11.1809.
10
Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN.Toll样受体（TLR）和CD40联合激活可诱导有效的CD8⁺T细胞扩增，且对I型干扰素的依赖性各不相同。
J Exp Med. 2004 Mar 15;199(6):775-84. doi: 10.1084/jem.20031591. Epub 2004 Mar 8.
引用本文的文献
1
A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations.奥拉帕利联合度伐利尤单抗治疗同源重组修复基因改变的晚期实体瘤的探索性 2 期研究。
Br J Cancer. 2023 Aug;129(3):475-485. doi: 10.1038/s41416-023-02311-0. Epub 2023 Jun 26.
2
Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy.下一代 CD40 激动型抗体在癌症免疫治疗中的应用
Front Immunol. 2022 Jul 13;13:940674. doi: 10.3389/fimmu.2022.940674. eCollection 2022.
3
Systemic inflammation is a determinant of outcomes of CD40 agonist-based therapy in pancreatic cancer patients.系统性炎症是 CD40 激动剂治疗胰腺癌患者结局的决定因素。
JCI Insight. 2021 Mar 8;6(5):145389. doi: 10.1172/jci.insight.145389.
4
Anti-CD40 antibody KPL-404 inhibits T cell-mediated activation of B cells from healthy donors and autoimmune patients.抗CD40抗体KPL-404可抑制来自健康供体和自身免疫性疾病患者的T细胞介导的B细胞活化。
Arthritis Res Ther. 2021 Jan 6;23(1):5. doi: 10.1186/s13075-020-02372-z.
5
An Overview of Advances in Cell-Based Cancer Immunotherapies Based on the Multiple Immune-Cancer Cell Interactions.基于多种免疫-肿瘤细胞相互作用的细胞基础癌症免疫疗法的进展概述。
Methods Mol Biol. 2020;2097:139-171. doi: 10.1007/978-1-0716-0203-4_10.
6
Association between the CD40 rs1883832 polymorphism and Graves' disease risk: a meta-analysis.CD40基因rs1883832多态性与格雷夫斯病风险的关联：一项荟萃分析。
EXCLI J. 2019 Jan 23;18:10-20. eCollection 2019.
7
Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy.CDX-1140 的研发：一种用于癌症免疫治疗的 CD40 激动型抗体。
Cancer Immunol Immunother. 2019 Feb;68(2):233-245. doi: 10.1007/s00262-018-2267-0. Epub 2018 Oct 31.
8
Ginkgolide C Alleviates Myocardial Ischemia/Reperfusion-Induced Inflammatory Injury via Inhibition of CD40-NF-κB Pathway.银杏内酯C通过抑制CD40-NF-κB通路减轻心肌缺血/再灌注诱导的炎症损伤。
Front Pharmacol. 2018 Feb 21;9:109. doi: 10.3389/fphar.2018.00109. eCollection 2018.
9
Metabolism-associated danger signal-induced immune response and reverse immune checkpoint-activated CD40 monocyte differentiation.代谢相关危险信号诱导的免疫反应及反向免疫检查点激活的CD40单核细胞分化。
J Hematol Oncol. 2017 Jul 24;10(1):141. doi: 10.1186/s13045-017-0504-1.
10
IL-21/anti-Tim1/CD40 ligand promotes B10 activity in vitro and alleviates bone loss in experimental periodontitis in vivo.IL-21/抗 Tim1/CD40 配体在体外促进 B10 活性，并在体内实验性牙周炎中减轻骨质流失。
Biochim Biophys Acta Mol Basis Dis. 2017 Sep;1863(9):2149-2157. doi: 10.1016/j.bbadis.2017.06.001. Epub 2017 Jun 3.
本文引用的文献
1
Plasticity and complexity of B cell responses against persisting pathogens.针对持续性病原体的B细胞反应的可塑性与复杂性。
Immunol Lett. 2014 Nov;162(1 Pt A):53-8. doi: 10.1016/j.imlet.2014.07.003. Epub 2014 Jul 25.
2
Helper T cell plasticity: impact of extrinsic and intrinsic signals on transcriptomes and epigenomes.辅助性T细胞可塑性：外在和内在信号对转录组和表观基因组的影响
Curr Top Microbiol Immunol. 2014;381:279-326. doi: 10.1007/82_2014_371.
3
Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.局部递送的 CD40 激动剂抗体在次级淋巴器官中积累，并根除实验性播散性膀胱癌。
Cancer Immunol Res. 2014 Jan;2(1):80-90. doi: 10.1158/2326-6066.CIR-13-0067. Epub 2013 Oct 21.
4
Engineering of a novel anti-CD40L domain antibody for treatment of autoimmune diseases.新型抗 CD40L 结构域抗体的工程改造用于治疗自身免疫性疾病。
J Immunol. 2014 May 1;192(9):4083-92. doi: 10.4049/jimmunol.1303239. Epub 2014 Mar 26.
5
Combined anti-CD40 and anti-IL-23 monoclonal antibody therapy effectively suppresses tumor growth and metastases.联合抗 CD40 和抗 IL-23 单克隆抗体治疗可有效抑制肿瘤生长和转移。
Cancer Res. 2014 May 1;74(9):2412-21. doi: 10.1158/0008-5472.CAN-13-1646. Epub 2014 Feb 20.
6
Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials.抗 CD40 介导的癌症免疫疗法：近期和正在进行的临床试验更新。
Immunopharmacol Immunotoxicol. 2014 Apr;36(2):96-104. doi: 10.3109/08923973.2014.890626. Epub 2014 Feb 21.
7
Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer.CD40 激动型抗体免疫疗法中缓释系统的疗效。
Vaccine. 2014 Mar 26;32(15):1654-60. doi: 10.1016/j.vaccine.2014.01.056. Epub 2014 Feb 7.
8
Costimulatory pathways in kidney transplantation: pathogenetic role, clinical significance and new therapeutic opportunities.肾移植中的共刺激途径：发病机制作用、临床意义和新的治疗机会。
Int Rev Immunol. 2014 May-Jun;33(3):212-33. doi: 10.3109/08830185.2013.829470. Epub 2013 Oct 15.
9
Targeting antigens to CD180 rapidly induces antigen-specific IgG, affinity maturation, and immunological memory.靶向 CD180 可迅速诱导抗原特异性 IgG、亲和力成熟和免疫记忆。
J Exp Med. 2013 Sep 23;210(10):2135-46. doi: 10.1084/jem.20130188. Epub 2013 Sep 9.
10
CD40 triggering induces strong cytotoxic T lymphocyte responses to heat-killed Staphylococcus aureus immunization in mice: a new vaccine strategy for staphylococcal mastitis.CD40 触发可诱导小鼠对热灭活金黄色葡萄球菌免疫产生强烈的细胞毒性 T 淋巴细胞反应：一种新的金黄色葡萄球菌乳腺炎疫苗策略。
Vaccine. 2012 Mar 9;30(12):2116-24. doi: 10.1016/j.vaccine.2012.01.039. Epub 2012 Jan 27.
Zotero 插件